Auditor General Delivers Report to the Public Accounts Committee on Audit of Long Term Care Facilities - Government of Newfoundland and Labrador

An advocate is concerned local communities are unable to access healthcare due to growing pressure on the public system. Kaitiaki Hauora - "guardians of health" in te reo Māori - will host the first public meeting in the Save Our Public Healthcare Roady on Sunday. Malcolm Mulholland and David Galler will travel from Bluff to Cape Reinga between 4 and 17 October. The tour will begin in Invercargill at 4.30pm on Sunday before heading to Gore, Dunedin, Timaru, Christchurch, Westport, Nelson, Lower Hutt, Masterton, New Plymouth, Whanganui, Palmerston North, Napier, Gisborne, Tauranga, Whakatāne, Taupō, Rotorua, Tokoroa, Hamilton, Thames, Auckland, Dargaville, Whangārei and Kaitaia. Mulholland told RNZ he hoped to hear from people about their local hospitals and access to healthcare, as well as what was happening to health services in their communities. "There's been no shortage of concern around what is happening at the moment, and we want to hear first-hand what the experiences have been of different communities around the country," he said.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.